Historical Archive

Question by the Hon. Scilipoti

ACT ROOM

INTERROGATION TO ANSWER WRITTEN 4/06677

Presentation data of the deed

Legislature: 16
Announcement session: 303 of the 31/03/2010

Signatories

First signatory: SCILIPOT DOMENICO
Group: ITALY OF VALUES
Signature Date: 31/03/2010

Recipients

Recipient ministry:

  • PRESIDENCY OF THE COUNCIL OF MINISTERS
  • MINISTRY OF LABOR AND SOCIAL POLICIES
  • MINISTRY OF ECONOMY AND FINANCE
  • MINISTRY OF ECONOMIC DEVELOPMENT
  • MINISTRY OF HEALTH
Process status:

IN PROGRESS

Chamber act

Interrogation to answer written 4-06677

submitted by

DOMENICO SCILIPOTI
Wednesday 31 March 2010, session no. 303
SCILIPOTS. –

To the President of the Council of Ministers, the Minister of Labor and Social Policies, the Minister of Economy and Finance, the Minister of Economic Development, the Minister of Health.

– To know – provided that:

a method has been developing for several years in the industrial sector which essentially aims to get rid of personnel, proceeding with collective redundancies of thousands of workers through transfers of company branches to "satellite" companies or companies created ad hoc to allow these operations;

in this way the legislation on collective redundancies is circumvented and workers are prevented from effectively protecting their rights, masking a dismissal with a fictitious continuity of employment relationship, destined to end in a short time with the definitive dismissal of the workers by the company, only ostensibly buyer, which often goes bankrupt or closes permanently; often the acquiring companies already have a balance sheet in the red at the time of acquiring the workers;

in the pharmaceutical sector, which is the sector with the highest industrial added value and which knows no crisis, for several years, in the opinion of the questioner, a substantial circumvention of the rules on collective redundancies has been going on through the abuse of the instrument of transfers business branch and mobility;

Marvecspharma has acquired numerous business units from major multinational pharmaceutical companies. Some of these operations are cited as examples;

on 31 Jan

Articoli correlati

Back to top button
Fedaiisf Federazione delle Associazioni Italiane degli Informatori Scientifici del Farmaco e del Parafarmaco